Scisparc Ltd Total Liabilities
Scisparc Ltd total liabilities. Based on the latest financial reports, Scisparc Ltd (SPRC) has total liabilities worth $2.48 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Scisparc Ltd (SPRC) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Scisparc Ltd (2006–2025)
Total liabilities of Scisparc Ltd from 2006 to 2025. This chart illustrates how Scisparc Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore SPRC long-term investments to assets to see how much of total assets are deployed in long-term investments.
Scisparc Ltd Competitors by Total Liabilities
The table below lists competitors of Scisparc Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lee Swee Kiat Group Bhd
KLSE:8079
|
Malaysia | RM31.18 Million |
|
Saudee Group Bhd
KLSE:5157
|
Malaysia | RM8.41 Million |
|
Radiopharm Theranostics Limited American Depositary Shares
NASDAQ:RADX
|
USA | $37.81 Million |
|
Vincit Group Oyj
HE:VINCIT
|
Finland | €23.49 Million |
|
LogProstyle Inc.
NYSE MKT:LGPS
|
USA | $21.24 Billion |
|
Matching Maximize Solution Public Company Limited
BK:MATCH
|
Thailand | ฿164.48 Million |
|
J and Friends Holdings Limited
NASDAQ:JF
|
USA | $22.85 Million |
|
Giga Media Ltd
NASDAQ:GIGM
|
USA | $3.06 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Scisparc Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SPRC asset base.
Liquidity & Leverage Metrics
Scisparc Ltd Total Liabilities Ratios Explained
Scisparc Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scisparc Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scisparc Ltd (2006–2025)
The table below shows the annual total liabilities of Scisparc Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.48 Million | +75.78% |
| 2024-12-31 | $1.41 Million | -11.72% |
| 2023-12-31 | $1.59 Million | -61.62% |
| 2022-12-31 | $4.16 Million | +134.14% |
| 2021-12-31 | $1.77 Million | +56.94% |
| 2020-12-31 | $1.13 Million | -0.79% |
| 2019-12-31 | $1.14 Million | -74.57% |
| 2018-12-31 | $4.48 Million | +280.88% |
| 2017-12-31 | $1.18 Million | +75.14% |
| 2016-12-31 | $672.02K | +31.56% |
| 2015-12-31 | $510.80K | +35.31% |
| 2014-12-31 | $377.51K | -45.74% |
| 2013-12-31 | $695.76K | -0.99% |
| 2012-12-31 | $702.74K | -52.58% |
| 2011-12-31 | $1.48 Million | -69.67% |
| 2010-12-31 | $4.89 Million | -25.73% |
| 2009-12-31 | $6.58 Million | +163.36% |
| 2008-12-31 | $2.50 Million | -56.97% |
| 2007-12-31 | $5.81 Million | +37.15% |
| 2006-12-31 | $4.23 Million | -- |
About Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil… Read more